A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
Molecules · 2023
DOI: 10.3390/molecules28093662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Yuetong Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Second Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer…. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Key Technology R&D Program, the Capital Health R&D Special Project, CAMS Innovation Fund for Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Paclitaxel-triethylenetetramine hexaacetic acid conjugate (PTX-TTHA), a novel semi-synthetic taxane, is designed to improve the water solubility and cosolvent toxicity of paclitaxel in several aminopolycarboxylic acid groups. In this study, the in vitro and in vivo antitumor effects and mechanisms of PTX-TTHA against triple-negative breast cancer (TNBC) and its intravenous toxicity were evaluated. Results showed the water solubility of PTX-TTHA was greater than 5 mg/mL, which was about 7140-fold higher than that of paclitaxel (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China.
- Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
- Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, China.
- Tianjin Institute for Drug Control, Tianjin 300070, China.
ORCID-Profile: Ge Hong
Förderung
- Tianjin Key Technology R&D Program
- the Capital Health R&D Special Project
- CAMS Innovation Fund for Medical Sciences
- Tianjin Key Technology R&D Program
- Capital Health R&D Special Project
Zitieren
APA
Liu, Y., Hong, G., Mao, L., Su, Z., Liu, T., & Liu, H. (2023). A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy. Molecules. https://doi.org/10.3390/molecules28093662
Vancouver
Liu Y, Hong G, Mao L, Su Z, Liu T, Liu H. A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy. Molecules. 2023. doi:10.3390/molecules28093662
BibTeX
@article{Liu2023,
author = {Liu, Yuetong and Hong, Ge and Mao, Lina and Su, Zhe and Liu, Tianjun and Liu, Hong},
title = {A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28093662}
}
EUVIMED